keyword
MENU ▼
Read by QxMD icon Read
search

antipsychotic switching

keyword
https://www.readbyqxmd.com/read/28101321/switching-away-from-pipotiazine-palmitate-a-naturalistic-study
#1
Feras Ali Mustafa
BACKGROUND: In March 2015, pipotiazine palmitate depot antipsychotic was globally withdrawn due to the shortage of its active ingredient. Thus, all patients receiving this medication had to be switched to an alternative antipsychotic drug. In this study we set to evaluate the process of switching away from pipotiazine palmitate within our clinical service, and its impact on hospitalization. METHODS: Demographic and clinical data on patients who were receiving pipotiazine palmitate in Northamptonshire at the time of its withdrawal were anonymously extracted from their electronic records and analyzed using descriptive statistics...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28072646/clozapine-treatment-of-olanzapine-induced-tardive-dyskinesia-a-case-report
#2
Dinesh Sangroula, Inderpreet Virk, Wali Mohammad, David A Kahn
Tardive dyskinesias (TD) are serious, often irreversible side effects of dopamine blocking agents, most commonly first-generation antipsychotics. No definitive treatment exists, with different interventions showing inconsistent results. We report a case of TD presenting after 12 years of olanzapine therapy in a 66-year-old Hispanic male with paranoid schizophrenia. The TD symptoms were successfully treated within a few weeks by switching to clozapine. Two cases of olanzapine-induced TD treated with clozapine have previously been reported, but in those cases, the symptom onset was quicker, ranging from a few months to a few years after initiation of olanzapine therapy, and the treatment response was relatively slower...
January 2017: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/28063386/attitudes-towards-and-rationale-for-antipsychotic-polypharmacy-among-psychiatrists-in-nigeria-characteristics-associated-with-high-reported-antipsychotic-polypharmacy
#3
B O James, J O Omoaregba, S O Raji, O E Imishue, K M Okonoda, Y I Nyamali, P A Famuyiwa, C U Correll
Antipsychotic polypharmacy (APP) is commonplace despite lacking evidence of its effectiveness. We aimed to identify psychiatrists' rationale for and attitudes towards APP and to determine if attitudes influence antipsychotic polypharmacy prescription rates in a survey of a nationally representative sample of Nigerian psychiatrists (of which a majority were senior trainees: 74.2%). Prescriber characteristics, practices and attitudes were compared in 'high' (>30%) vs. 'low' (≤30%) antipsychotic polypharmacy prescribers and results were adjusted for multiple comparisons...
December 27, 2016: Psychiatry Research
https://www.readbyqxmd.com/read/28056018/the-effectiveness-of-pharmacological-and-non-pharmacological-interventions-for-improving-glycaemic-control-in-adults-with-severe-mental-illness-a-systematic-review-and-meta-analysis
#4
Johanna Taylor, Brendon Stubbs, Catherine Hewitt, Ramzi A Ajjan, Sarah L Alderson, Simon Gilbody, Richard I G Holt, Prakash Hosali, Tom Hughes, Tarron Kayalackakom, Ian Kellar, Helen Lewis, Neda Mahmoodi, Kirstine McDermid, Robert D Smith, Judy M Wright, Najma Siddiqi
People with severe mental illness (SMI) have reduced life expectancy compared with the general population, which can be explained partly by their increased risk of diabetes. We conducted a meta-analysis to determine the clinical effectiveness of pharmacological and non-pharmacological interventions for improving glycaemic control in people with SMI (PROSPERO registration: CRD42015015558). A systematic literature search was performed on 30/10/2015 to identify randomised controlled trials (RCTs) in adults with SMI, with or without a diagnosis of diabetes that measured fasting blood glucose or glycated haemoglobin (HbA1c)...
2017: PloS One
https://www.readbyqxmd.com/read/28044455/health-care-resource-utilization-and-costs-of-california-medicaid-patients-with-schizophrenia-treated-with-paliperidone-palmitate-once-monthly-or-atypical-oral-antipsychotic-treatment
#5
Jacqueline A Pesa, Dilesh Doshi, Li Wang, Huseyin Yuce, Onur Baser
OBJECTIVE: To compare all-cause health care utilization and costs between patients with schizophrenia treated with once-monthly paliperidone palmitate (PP1M; Invega® Sustenna(®)) and atypical oral antipsychotic therapy (OAT). METHODS: This was a retrospective claims-based analysis among adult California Medicaid (Medi-Cal) patients with schizophrenia having ≥2 claims for PP1M or OAT from 01JUL2009-31DEC2013 and continuous health plan enrollment for ≥1 year pre- and post-index date (PP1M or OAT initiation date)...
January 3, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28044008/immediate-vs-gradual-discontinuation-in-antipsychotic-switching-a-systematic-review-and-meta-analysis
#6
Hiroyoshi Takeuchi, Navot Kantor, Hiroyuki Uchida, Takefumi Suzuki, Gary Remington
BACKGROUND: Antipsychotic switching is routine in clinical practice, although it remains unclear which is the preferable switching method: immediate discontinuation of the current antipsychotic or a gradual tapering approach. The first strategy has been implicated in rebound/withdrawal symptoms and emergence/exacerbation of symptoms, whereas the gradual approach is thought to pose a risk of additive or synergistic side effects if employed in the context of a crossover approach. METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched...
January 1, 2017: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/28008301/iloperidone-in-the-treatment-of-schizophrenia-an-evidence-based-review-of-its-place-in-therapy
#7
REVIEW
Fernanda S Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo
INTRODUCTION: Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as iloperidone, can provide more effective, tolerable and safer strategies. AIM: To review the evidence for the clinical impact of iloperidone on the treatment of patients with schizophrenia...
2016: Core Evidence
https://www.readbyqxmd.com/read/28008256/blonanserin-treatment-in-patients-with-methamphetamine-induced-psychosis-comorbid-with-intellectual-disabilities
#8
Kosuke Okazaki, Manabu Makinodan, Kazuhiko Yamamuro, Tomoyo Takata, Toshifumi Kishimoto
OBJECTIVE: Methamphetamine (MA) use has recently been associated with high levels of psychiatric hospitalization and serious social dysfunction. MA use causes frequent psychotic symptoms, which can be treated with antipsychotics. However, people with intellectual disabilities (ID) are vulnerable to adverse effects resulting from treatment with antipsychotic medications. METHOD: We report two cases of MA-induced psychosis (MAP) in patients with ID who were treated with the antipsychotic blonanserin...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/27964751/neurotoxicity-and-nephrotoxicity-caused-by-combined-use-of-lithium-and-risperidone-a-case-report-and-literature-review
#9
Chih-Wei Hsu, Yu Lee, Chun-Yi Lee, Pao-Yen Lin
BACKGROUND: Combination lithium, a mood stabilizer, and risperidone, an atypical antipsychotic drug, is widely used for treatment of psychotic disorders. Rare reports concern severe adverse drug reaction in multiple organic systems with their combined use. We report two episodes of neurotoxicity and nephrotoxicity in a patient following the combined use of lithium and risperidone. CASE PRESENTATION: A 55-year-old male had a diagnosis of schizoaffective disorder at the age of 51...
December 14, 2016: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/27875914/second-generation-antipsychotics-in-real-life-paediatric-patients-adverse-drug-reactions-and-clinical-outcomes-of-drug-switch
#10
Concetta Rafaniello, Marco Pozzi, Simone Pisano, Carmen Ferrajolo, Silvana Bertella, Liberata Sportiello, Carla Carnovale, Maria Giuseppa Sullo, Dario Cattaneo, Marta Gentili, Renata Rizzo, Antonio Pascotto, Elisa Mani, Laura Villa, Maria Pia Riccio, Serena Sperandeo, Renato Bernardini, Carmela Bravaccio, Emilio Clementi, Massimo Molteni, Francesco Rossi, Sonia Radice, Annalisa Capuano
OBJECTIVE: Gap in knowledge on benefit/risk ratio of second generation antipsychotics (SGA) in the paediatric population represents a challenge for the scientific community. This study aims to analyse all suspected adverse drug reactions (ADRs) to SGA observed during the study period; compare the safety profiles of risperidone and aripiprazole; evaluate the effect of switching from risperidone to aripiprazole or to a first generation antipsychotic (FGA). METHODS: Prospective analysis of spontaneously reported ADRs concerning 184 paediatric outpatients between 2012 and 2014...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27855483/prediction-of-relapse-after-discontinuation-of-antipsychotic-treatment-in-alzheimer-s-disease-the-role-of-hallucinations
#11
Anjali N Patel, Seonjoo Lee, Howard F Andrews, Gregory H Pelton, Susan K Schultz, David L Sultzer, Jacobo Mintzer, Danilo de la Pena, Sanjay Gupta, Sylvia Colon, Corbett Schimming, Bruce Levin, D P Devanand
OBJECTIVE: In Alzheimer's disease, antipsychotic medications are often used for a period, with relief of symptoms, and then discontinued, after which relapse may occur. The authors sought to determine which neuropsychiatric symptoms predict relapse. METHOD: In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patients with Alzheimer's disease and symptoms of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who responded (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo for 16 weeks, or to receive placebo for 32 weeks...
November 18, 2016: American Journal of Psychiatry
https://www.readbyqxmd.com/read/27848269/evidence-based-pharmacotherapy-of-treatment-resistant-unipolar-depression
#12
Markus Dold, Siegfried Kasper
Treatment resistance to the antidepressive pharmacotherapy represents one of the most important clinical challenges in the pharmacological management of unipolar depression. In this review, we aimed to summarise the evidence for various pharmacological treatment options in therapy-resistant unipolar depression derived from clinical trials, systematic reviews, meta-analyses and treatment guidelines. The first measure in case of insufficient response to the initial antidepressant monotherapy contains the debarment of 'pseudo-resistance', potentially caused by inadequate dose and treatment duration of the antidepressant, insufficient plasma levels, non-compliance of the patient regarding medication intake or relevant psychiatric and/or somatic comorbidities...
November 16, 2016: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/27828697/aripiprazole-induced-hyperlipidemia-an-update
#13
Caroline Tarraf, Wadih J Naja
OBJECTIVE: To review the literature on the metabolic side effects of aripiprazole. Three cases of aripiprazole-induced hypertriglyceridemia are also presented. DATA SOURCES: A search was conducted of English-language articles and abstracts (meta-analyses, randomized controlled trials, clinical trials, naturalistic open-label trials, reviews, and case reports) published up to August 31, 2014, in electronic databases (PubMed, MEDLINE). STUDY SELECTION: Free-text and MeSH search keywords included aripiprazole, cholesterol, triglyceride, lipid profile, hyperlipidemia, and hypercholesterolemia and their differing terminations and combinations...
August 25, 2016: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/27815602/switching-from-oral-atypical-antipsychotic-monotherapy-to-paliperidone-palmitate-once-monthly-in-non-acute-patients-with-schizophrenia-a-prospective-open-label-interventional-study
#14
Andreas Schreiner, Asaf Caspi, Paul Bergmans, Pierre Cherubin, Sofia Keim, Elsa Lara, Irina Pinchuk, Daniel Schuepbach, Sajid Suleman, Ludger Hargarter
RATIONALE: Long-acting injectable antipsychotic therapies may offer benefits over oral antipsychotics in patients with schizophrenia. OBJECTIVE: This study aimed to explore the safety, tolerability, and treatment response of paliperidone palmitate once-monthly in non-acute but symptomatic adult patients switched from previously unsuccessful monotherapy with frequently used oral atypical antipsychotics. METHODS: This was a post hoc analysis of a prospective, interventional, single-arm, international, multicenter, open-label, 6-month study...
January 2017: Psychopharmacology
https://www.readbyqxmd.com/read/27800283/prolactin-levels-after-switching-to-paliperidone-palmitate-in-patients-with-schizophrenia
#15
Masaru Nakamura, Takahiko Nagamine, Goro Sato, Kazue Besho
Objective: The aim of this study was to investigate the tolerability and efficacy of paliperidone palmitate and its effect on the levels of prolactin in patients with schizophrenia. Method: A prospective study was carried out in 22 Japanese middle-aged patients with schizophrenia who were switched from paliperidone-extended release or risperidone long-acting injectable to paliperidone palmitate for a minimum of 12 months. Psychotic symptoms using the 18-item Brief Psychiatric Rating Scale, extrapyramidal symptoms using 9-item Drug-induced Extrapyramidal Symptoms Scale, and plasma prolactin levels using fasting blood samples were assessed at Baseline, and one, three, six, and 12 months...
May 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27799749/physician-and-patient-benefit-risk-preferences-from-two-randomized-long-acting-injectable-antipsychotic-trials
#16
Eva G Katz, Brett Hauber, Srihari Gopal, Angie Fairchild, Amy Pugh, Rachel B Weinstein, Bennett S Levitan
PURPOSE: To quantify clinical trial participants' and investigators' judgments with respect to the relative importance of efficacy and safety attributes of antipsychotic treatments for schizophrenia, and to assess the impact of formulation and adherence. METHODS: Discrete-choice experiment surveys were completed by patients with schizophrenia and physician investigators participating in two phase-3 clinical trials of paliperidone palmitate 3-month long-acting injectable (LAI) antipsychotic...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27776390/amisulpride-switching-in-schizophrenic-patients-who-showed-suboptimal-effect-and-or-tolerability-to-current-antipsychotics-in-a-naturalistic-setting-an-explorative-study
#17
Yongmin Kim, Sheng-Min Wang, Kyung-Phil Kwak, Ho-Kyoung Yoon, Chi-Un Pae, Jung-Jin Kim, Won-Myong Bahk
Objective: Despite numerous atypical antipsychotics (AAP) available, many patients with schizophrenia still experience lack of efficacy and persistent side-effects. Switching from one AAP to another with a different side-effect profile has become a common clinical strategy. We aimed to investigate effect of switching to amisulpride in patients who showed suboptimal effect and /or tolerability to current antipsychotics treatment. Methods: This was a 6-week, prospective, multicenter, open-label, flexible-dose study in patients with schizophrenia...
November 30, 2016: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27738379/effects-of-discontinuation-of-paliperidone-long-acting-injectable-after-switching-from-risperidone-long-acting-injectable-switching
#18
Takafumi Watanabe, Atsurou Yamada
BACKGROUND: Risperidone long-acting injection (RLAI) is increasingly being switched to paliperidone palmitate (PP) because of several benefits. However, this switching is not always successful. METHODS: We examined patient profiles following discontinuation of PP after switching from RLAI. We collected the electronic records of 24 patients with schizophrenia who had switched from RLAI to PP treatment at our hospital between November 2013 and March 2014. Twelve patients continued PP injection for over 1 year (PP-continuers), the other 12 patients discontinued within 1 year (PP-discontinuers), and both groups were followed up until December 31, 2014...
August 15, 2016: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/27659709/palmitoylation-of-the-carboxyl-terminal-tail-of-dopamine-d4-receptor-is-required-for-surface-expression-endocytosis-and-signaling
#19
Xiaowei Zhang, Kyeong-Man Kim
The amino acid sequences and signaling pathways of D2-like dopamine receptors (D2R, D3R, and D4R) are highly conserved. D4R has been suggested to be associated with novelty seeking, and binds with high affinity to an atypical antipsychotic drug with fewer motor function-related side effects than typical neuroleptics. A study comparing D2R and D3R reported that palmitoylation is important for the proper functioning of D3R. Although D4R is a member of the D2-like receptor family, its palmitoylation status and the functional significance of any such posttranslational modification are unknown...
October 14, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27658832/treatment-patterns-of-schizophrenia-based-on-the-data-from-seven-central-and-eastern-european-countries
#20
Monika Szkultecka-Dębek, Katarzyna Miernik, Jarosław Stelmachowski, Miro Jakovljević, Vlado Jukić, Kaire Aadamsoo, Sven Janno, István Bitter, Judit Tolna, Marek Jarema, Slobodan Jankovic, Jan Pecenak, Livia Vavrusova, Rok Tavčar, Jacek Walczak, Darren Talbot, Joanna Augustyńska
OBJECTIVE: The aim is to analyze how schizophrenia is pharmacologically treated in seven CEE countries: Croatia, Estonia, Hungary, Poland, Serbia, Slovakia and Slovenia. METHODS: Psychiatrists from selected centers in each of participating countries were asked to complete a pre-defined questionnaire on their current clinical practice. Information on protocols and resource utilization in schizophrenia treatment was included and derived from randomly selected patient medical records...
September 2016: Psychiatria Danubina
keyword
keyword
88298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"